5VGO

Bruton's tyrosine kinase (BTK) with compound G-744


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.621 Å
  • R-Value Free: 0.184 
  • R-Value Work: 0.161 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.

Wang, X.Barbosa, J.Blomgren, P.Bremer, M.C.Chen, J.Crawford, J.J.Deng, W.Dong, L.Eigenbrot, C.Gallion, S.Hau, J.Hu, H.Johnson, A.R.Katewa, A.Kropf, J.E.Lee, S.H.Liu, L.Lubach, J.W.Macaluso, J.Maciejewski, P.Mitchell, S.A.Ortwine, D.F.DiPaolo, J.Reif, K.Scheerens, H.Schmitt, A.Wong, H.Xiong, J.M.Xu, J.Zhao, Z.Zhou, F.Currie, K.S.Young, W.B.

(2017) ACS Med Chem Lett 8: 608-613

  • DOI: 10.1021/acsmedchemlett.7b00103

  • PubMed Abstract: 
  • In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds th ...

    In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds that improved upon the druglike properties of our previous chemical matter. Compounds exemplified by G-744 are highly potent, selective for Btk, metabolically stable, well tolerated, and efficacious in an animal model of arthritis.


    Organizational Affiliation

    Genentech, Inc., Research and Early Development, 1 DNA Way, South San Francisco, California 94080, United States.,Gilead Sciences (formerly CGI Pharmaceuticals), 199 East Blaine Street, Seattle, Washington 98102, United States.,ChemPartner, No. 1 Building, 998 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China 201203.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein kinase BTK
A
271Homo sapiensMutation(s): 0 
Gene Names: BTK (AGMX1, ATK, BPK)
EC: 2.7.10.2
Find proteins for Q06187 (Homo sapiens)
Go to Gene View: BTK
Go to UniProtKB:  Q06187
Small Molecules
Ligands 4 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
A
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
GOL
Query on GOL

Download SDF File 
Download CCD File 
A
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
PG0
Query on PG0

Download SDF File 
Download CCD File 
A
2-(2-METHOXYETHOXY)ETHANOL
PEG 6000
C5 H12 O3
SBASXUCJHJRPEV-UHFFFAOYSA-N
 Ligand Interaction
9B1
Query on 9B1

Download SDF File 
Download CCD File 
A
2-[2-(hydroxymethyl)-3-{1-methyl-6-oxo-5-[(pyrimidin-4-yl)amino]-1,6-dihydropyridin-3-yl}phenyl]-6,6-dimethyl-3,4,6,7-tetrahydro-2H-cyclopenta[4,5]thieno[2,3-c]pyridin-1(5H)-one
C29 H29 N5 O3 S
QAESSIFTPVEYRY-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
9B1Ki: 1.28 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.621 Å
  • R-Value Free: 0.184 
  • R-Value Work: 0.161 
  • Space Group: P 61
Unit Cell:
Length (Å)Angle (°)
a = 108.314α = 90.00
b = 108.314β = 90.00
c = 42.570γ = 120.00
Software Package:
Software NamePurpose
XDSdata reduction
REFMACphasing
Aimlessdata scaling
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2017-04-11 
  • Released Date: 2017-07-05 
  • Deposition Author(s): Yu, C., Eigenbrot, C.

Revision History 

  • Version 1.0: 2017-07-05
    Type: Initial release